Programs
Description
PRE-CLINICAL
IND ENABLING
PHASE 1
Phase 2
PHASE 3
GM-2505: Short-Acting
5-HT2AR Agonist
2 hour treatment duration
Indications: Depression
Non-hallucinogenic neuroplastogen
Indications: Depression, Anxiety
Improved Cardiac Safety Profile, Improved Efficacy
Indications: Opioid Use Disorder, PTSD, TBI
Orally Bioavailable, Rapid-acting, Non Dissociative, Potential At-Home Use
Indications: Depression
Neuroplastogens
GM-1020: NMDAR Antagonist
GM-3009: Safer Ibogaine Analog
Program
GM-1020: Oral NMDAR Antagonist
Description
Orally Bioavailable, Rapid-acting, Non Dissociative, Potential At-Home Use
Indications: Depression, Bipolar Depression and Others
Phase
Pre-Clinical|IND| Phase 1| Phase 2
Program
GM-2505: Short Acting 5-HT2A Agonist
Description
60-90 minute duration
Indications: Depression, Anxiety and Others
Phase
Pre-Clinical|IND| Phase 1| Phase 2
Program
GM-5022: Oral Neuroplastogen
Description
Non-hallucinogenic neuroplastogen
Indications: Depression, Anxiety and Others
Phase
Discovery | Pre-Clinical | IND | Phase 1
Program
GM-3009: Safer Ibogaine Analogs
Description
Improved Cardiac Safety Profile, Improved Efficacy
Indications: Opioid Use Disorder, PTSD, TBI
Phase
Discovery | Pre-Clinical | IND | Phase 1
